Seroatlas · Human Serome Atlas

IDH2

Isocitrate dehydrogenase [NADP], mitochondrial

Also known as: IDH-2, IDHP_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P48735
Gene
IDH2
Ensembl
ENSG00000182054
Chromosome
15
Canonical length
452 aa
Protein class
Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
Subcellular location
Mitochondria
Quaternary structure
Homodimer

OverviewNCBI Gene

Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP(+)-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the mitochondria. It plays a role in intermediary metabolism and energy production. This protein may tightly associate or interact with the pyruvate dehydrogenase complex. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]

Canonical amino-acid sequenceUniProt

452 residues, UniProt reviewed canonical sequence.

>P48735|IDH2
     1  MAGYLRVVRS LCRASGSRPA WAPAALTAPT SQEQPRRHYA DKRIKVAKPV VEMDGDEMTR
    61  IIWQFIKEKL ILPHVDIQLK YFDLGLPNRD QTDDQVTIDS ALATQKYSVA VKCATITPDE
   121  ARVEEFKLKK MWKSPNGTIR NILGGTVFRE PIICKNIPRL VPGWTKPITI GRHAHGDQYK
   181  ATDFVADRAG TFKMVFTPKD GSGVKEWEVY NFPAGGVGMG MYNTDESISG FAHSCFQYAI
   241  QKKWPLYMST KNTILKAYDG RFKDIFQEIF DKHYKTDFDK NKIWYEHRLI DDMVAQVLKS
   301  SGGFVWACKN YDGDVQSDIL AQGFGSLGLM TSVLVCPDGK TIEAEAAHGT VTRHYREHQK
   361  GRPTSTNPIA SIFAWTRGLE HRGKLDGNQD LIRFAQMLEK VCVETVESGA MTKDLAGCIH
   421  GLSNVKLNEH FLNTTDFLDT IKSNLDRALG RQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IDH2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.28
Highest tissue expression
1,504 nTPM

Expression across tissuesHPA

Tissue

  • tongue: 1,504 nTPM
  • skeletal muscle: 1,220 nTPM
  • heart muscle: 462 nTPM
  • liver: 251 nTPM
  • kidney: 181 nTPM
  • stomach: 168 nTPM

Single-cell type

  • parietal cells: 1,126 nCPM
  • cytotrophoblasts: 989 nCPM
  • extravillous trophoblasts: 855 nCPM
  • syncytiotrophoblasts: 766 nCPM
  • migrating cytotrophoblasts: 573 nCPM
  • paneth cells: 437 nCPM

Immune cell

  • non-classical monocyte: 254 nTPM
  • intermediate monocyte: 199 nTPM
  • total PBMC: 163 nTPM
  • myeloid DC: 137 nTPM
  • memory CD8 T-cell: 120 nTPM
  • classical monocyte: 113 nTPM

Brain region

  • choroid plexus: 145 nTPM
  • thalamus: 138 nTPM
  • basal ganglia: 125 nTPM
  • medulla oblongata: 115 nTPM
  • midbrain: 112 nTPM
  • cerebellum: 104 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about IDH2.

Disease | AllUniProt

Conditions IDH2 is implicated in, by any mechanism.

Disease | GeneticClinVar

6 pathogenic / likely-pathogenic of 292 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.38
gnomAD pLI
0.88
gnomAD missense Z
1.34
DepMap mean gene effect
-0.03
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of IDH2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IDH2 as an antibody target. Whether an autoantibody or antibody against IDH2 could matter depends on whether native IDH2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IDH2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label IDH2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/IDH2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...